These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35677519)

  • 41. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Chen J; Zhou C; Long Y; Yin X
    Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TACE and conformal radiotherapy
    Féray C; Campion L; Mathurin P; Archambreaud I; Mirabel X; Bronowicki JP; Rio E; Perret C; Mineur L; Oberti F; Touchefeu Y; Gournay J; Regnault H; Edeline J; Rode A; Hillion P; Blanc JF; Khac EN; Azoulay D; Luciani A; Preglisasco AG; Faurel-Paul E; Auble H; Mornex F; Merle P
    JHEP Rep; 2023 Apr; 5(4):100689. PubMed ID: 36937990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Liver Cancer; 2017 Jun; 6(3):227-235. PubMed ID: 28626733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
    Zhang L; Hu P; Chen X; Bie P
    PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
    Xie Y; Tian H; Xiang B; Zhang Y; Liu J; Cai Z; Xiang H
    Medicine (Baltimore); 2021 Aug; 100(33):e26958. PubMed ID: 34414963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib plus transarterial chemoembolization
    Yang HJ; Ye B; Liao JX; Lei L; Chen K
    World J Hepatol; 2024 Jan; 16(1):91-102. PubMed ID: 38313249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation.
    Zhang X; Cai L; Fang J; Chen F; Pan F; Zhang K; Huang Q; Huang Y; Li D; Lv L; Chen M; Yan R; Lai Y; Peng Y; Wu Z
    Front Oncol; 2022; 12():1101351. PubMed ID: 36713526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.
    Cao Y; Sun T; Guo X; Ouyang T; Kan X; Chen L; Liang B; Wang M; Zheng C
    Front Oncol; 2021; 11():673378. PubMed ID: 34414104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Sun T; Chen L; Kan X; Ren Y; Cao Y; Zhang W; Lu H; Zheng C
    J Oncol; 2022; 2022():1255133. PubMed ID: 35356254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
    Zheng L; Fang S; Wu F; Chen W; Chen M; Weng Q; Wu X; Song J; Zhao Z; Ji J
    Front Mol Biosci; 2020; 7():609322. PubMed ID: 33521054
    [No Abstract]   [Full Text] [Related]  

  • 59. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
    Ju S; Wang W; Chen P; Li F; Li H; Wang M; Han X; Ren J; Duan X
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101859. PubMed ID: 34999249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization.
    Wang H; Li B; Wang Y; Zhang J; Wu Y; Fan W; Li J
    J Cancer Res Ther; 2020; 16(2):301-308. PubMed ID: 32474517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.